Dong-A Socio Holdings
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dong-A Socio Holdings
From being generics-focused to becoming innovators and leaders in biosimilars, Scrip takes a look at how the Korean pharma sector and environment have evolved over the past 10 years.
A Phase I study will compare the pharmacokinetics, safety and tolerability of Meiji and Dong-A’s DMB-3115 ustekinumab biosimilar candidate against Janssen’s Stelara reference psoriasis and Crohn’s disease brand.
Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs
A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma.
Japan’s first biosimilar teriparatide has been approved for Mochida Pharmaceutical, while competition in the darbepoetin alfa arena looks set to step up following two recent authorizations.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
- OTC, Consumer
In Vitro Diagnostics
- Chemistry, Immunoassay
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Dong-A Pharmaceutical Co., Ltd (Dong-A Pharm)
- Dong-A Science Technology Co., Ltd (Dong-A ST)
- Dong-A Socio Group
- JCOM Co. Ltd.
- Mezzion Co. Ltd.